Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Core Insights - Armata Pharmaceuticals announced positive topline results from its Phase 2 "Tailwind" trial for AP-PA02, a novel inhaled multi-phage therapeutic targeting chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients [1][5] Study Design and Results - The Tailwind study was a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety, pharmacokinetics, and efficacy of inhaled AP-PA02, conducted in two parallel cohorts [2] - Cohort A received AP-PA02 as monotherapy, while Cohort B received it in combination with inhaled antipseudomonal antibiotics, with dosing every 12 hours for 10 days and follow-up for approximately four weeks [2] - A post-hoc intent-to-treat analysis showed a statistically significant reduction in P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015) for AP-PA02 compared to placebo, indicating its effectiveness [3] - Approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in P.a., while no reduction was observed in placebo subjects [3] Safety Profile - Safety data indicated that inhaled AP-PA02 was well-tolerated, with treatment-emergent adverse events being mild and self-limiting, although one serious adverse event was reported [4] Company Overview - Armata Pharmaceuticals is focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections, with a pipeline that includes candidates for Pseudomonas aeruginosa and Staphylococcus aureus [6]